MAPT and early-onset autosomal dominant Alzheimer disease: Together, these studies show that MC uses its ability to inhibit serine/threonine protein phosphatases PP1 and PP2A to accelerate Alzheimer’s disease pathology, increasing the phosphorylation of key enzymes as well as tau protein itself to increase the accumulation of β-amyloid plaques and Tau NFTs (Table 1).